一种基于同时检测脂蛋白相关磷脂酶A（Lp-PLA）和超敏C反应蛋白（HsCRP）的用于筛查冠状动脉粥样硬化的双标记时间分辨荧光免疫分析（TRFIA）。
A dual-label time-resolved fluorescence immunoassay (TRFIA) for screening of Coronary atherosclerosis based on simultaneous detection of Lp-PLA and HsCRP.
作者信息
Zhang Zhong, Liu Xiaozhu, Li Yinfeng, Huang Ruolan, Wang Ling, Li Laiqing, Chen Cuicui, Ou Lijun, Chang Xiao, Qiao Qiujie, Chen Mingtai
机构信息
Department of Cardiovascular, Shenzhen Chinese Traditional Medical Hospital, Shenzhen 518033, Guangdong, China.
School of Light Industry Engineering, Guizhou Institute of Industry, Guiyang, 550000, China.
出版信息
Immunol Lett. 2017 Feb;182:12-17. doi: 10.1016/j.imlet.2016.12.004. Epub 2016 Dec 23.
Atherosclerosis is the underlying cause of most coronary events. The conventional method for coronary atherosclerosis detection is morphological examination or coronary arterionyraphy. These methods are complex and time-consuming. In this study a two-step dual-label TRFIA was developed for the simultaneous detection of Lp-PLA and hsCRP in a single run. The performance of this assay was first evaluated using clinical serum samples, and then compared with commercialized kits. The sensitivity of this assay for Lp-PLA2 detection was 1ng/mL (dynamic range, 0-1000U/L), and the sensitivity for hsCRP detection was 1mg/L (dynamic range, 1-1000mg/L). High correlation coefficients (R) were obtained between the present dual-label TRFIA and commercially available kits(R=0.99 for LP-PLA2 and hsCRP). The present dual-label TRFIA has high sensitivity, specificity, and accuracy in clinical sample analysis. It is a good alternative to the single-label diagnostic methods.
动脉粥样硬化是大多数冠状动脉事件的根本原因。传统的冠状动脉粥样硬化检测方法是形态学检查或冠状动脉造影。这些方法复杂且耗时。在本研究中，开发了一种两步双标记时间分辨荧光免疫分析方法，用于在一次运行中同时检测Lp-PLA和hsCRP。首先使用临床血清样本评估该检测方法的性能，然后与商业化试剂盒进行比较。该检测方法对Lp-PLA2检测的灵敏度为1ng/mL（动态范围，0-1000U/L），对hsCRP检测的灵敏度为1mg/L（动态范围，1-1000mg/L）。本双标记时间分辨荧光免疫分析方法与市售试剂盒之间获得了高相关系数（R）（Lp-PLA2和hsCRP的R均为0.99）。本双标记时间分辨荧光免疫分析方法在临床样本分析中具有高灵敏度、特异性和准确性。它是单标记诊断方法的良好替代方法。
Zotero 插件